2Raj RS,Najeeb S,Aruna R,et al.Primary plasma cell leukemia occuring in the young[J].Indian J Cancer,2003,40(3):116-117.
3Vera-Ojeda J,Garcia-Ruiz Esparza MA,Eosas-Cabral A,et al.Intermediate doses of melphalan and dexamethasone are better than vincristine,adrimycin and dexamethasone(VAD) and poly chemotherapy for the treatment of primary plasma cell leukemia[J].Ann Hematol,2002,81(7):362-367.
5Hovenga S,Wolf de J,Klip H,et al.Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD,high-dose cyclophosphamide and EDAP courses:a report of three cases and a review of the literature[J].Bone Marrow Transplant,1997,20(10):901-904.
6Robak T,Urbanskarys H,Robak E,et al.Aggressive primary plasma cell leukemia with skin manifestation,trisomy 8 and molecular oligoclonal features[J].Leuk Lympho,2002,43(5):1067-1073.
7Saccaro S,fonseca R,Veillon DM,et al.Primary plasma cell leukemia:report of 17 new cases treated with autologous or allogeneic stem cell transplantation and review of the literature[J].Am J Hematol,2005,78(4):288-294.
9Avet-Loiseau H,Daviet A,Brigaudeau C,et al.Cytogenetic,interphase,and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia:a study of 40 patients at diagnosis.on behalf of the Intergroupe Francophone du Myelome and the groupe Francais de Cytogenetique Hematologique[J].Blood,2001,97(3):822-825.
1Kyle RA, Maldonado JE, Baynd ED. Plasma cell leukaemia: report on 17 cases. Arch Intern Med, 1974,133:813-818.
2Noel P,Kyle RA. Plasma cell leukaemia:an evaluation of response to therapy. Am J Med, 1987,83:1062-1069.
3Regis C, Daniele S, Reda B, et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res, 2001,25:103-107.
4Garcia-Sanz BR, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood, 1999,93:1032-1037.
5Bernasconi C, Castelli G, Pagnucco G, et al. Plasma cell leukaemia:a report of 15 patients. Eur J Haematol,1989,51Suppl:76-77.
6Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A,et al. Intermediate doses of melphalan and dexamethasone better than vincrstine,adriamycin, and dexamethasone(VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol, 2002, 81:362-367.
7Hovenga S, de Wolf JT, Klip H, et al. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD,high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature. Bone Marrow Transplant, 1997,20:901-904.
8Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 1999,341:1565-1571.
9Hideshima T, Chauhan D, Podar K, et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol,2001,28:607-612.
10Strasser K, Ludwig H. Thalidomide treatment in multiple myeloma.Blood Rev,2002,16: 207 -215.
6Chan S M,George T,Cherry A M,et al.Complete remission of primaryplasma ceil leuk emi a with bortezomib,doxombicin,and dexamethasone:a case report[J].Cases J,2009,2(1):121.
7Al-Nawakil C,Tamburini J,Bardet V,et al.Bortezomib,doxorubidnand dexamethasone association is an efective option for plasmacel leukemia induction therapy[J].Leuk Lymphoma,2008,49(10):2 012-2 014.
8Muto P,Rossini F,Gay F,et al.Efficacy and safety of bortezomib in patients with plasma cell leukemia[J].Cancer,2007,109(10):2 285-2 290.
9Valentini CG, Bozzoli V, Fianchi L, et al. Primary plasma cell leukemia followed by testicular plasmacytoma[J]. Int J Hematol, 2011, 93(2): 224-227.
10D'Arena G, Valentini CG, Pietrantuono G, et al. Frontline chemotherapy with bortezomib - containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party[J]. Ann Oneol, 2012, 23(6): 1499- 1502.
